Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP, Chief Financial Officer | April 01, 2026 | April 02, 2026 |
| TAPESTRY, INC.TPR · Entity 2309 | Director | November 13, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 159,248 |
Ending reported balance
After 2026-04-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-01 · Sale · Disposed 25,519 · Balance 163,729 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. F2: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Row 2 · 2026-04-01 · Sale · Disposed 4,481 · Balance 159,248 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025. F3: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBMS Savings and Investment Program | 294.42 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 294.42 F4: Based on recent 401(k) plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025.
F2: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F3: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F4: Based on recent 401(k) plan statement.
TAPESTRY, INC.
Report date November 13, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,347 |
Reported balance
After 2025-11-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-11-13 · Grant · Acquired 1,985 · Balance 7,347 F1: All of these securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of these securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 13, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-11-20 · Grant · Acquired 6,652 · Balance 20,560 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 11,088 · Balance 31,648 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 25,484 · Balance 57,132 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 57,132 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 195 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.19 · Expires 2028-08-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 103,913 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 49,895 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 39,642 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F3: This option was fully exercisable.
F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2021 Filed Jan 4, 2022 23:22 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 47,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-22-000017 · wf-form4_164133854058540.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the Merger, all outstanding Celgene Corporation Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 23:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 8,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000230 · wf-form4_163883323201870.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,584 Underlying: Common Stock, $0.10 par value · 8,792 shares Expires 2023-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 23:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,498 | $55.41 | $249,234.18 |
DisclosureSEC source: 0000014272-21-000230 · wf-form4_163883323201870.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,302 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 23:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 8,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000230 · wf-form4_163883323201870.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 59,691 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · derivative · entry 9 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 59,691 shares Expires 2028-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 4,129 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · derivative · entry 8 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,214 Underlying: Common Stock, $0.10 par value · 4,129 shares Expires 2028-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 6,180 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · derivative · entry 7 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,063 Underlying: Common Stock, $0.10 par value · 6,180 shares Expires 2028-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 59,691 | $67.00 | $3,999,297.00 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · nonDerivative · entry 5 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,008 F2 · shares: 59,691 shares were sold in an exercise and sell transaction, covering the exercise price and taxes in accordance with the broker's procedures. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $66.865 to $67.09, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F2 · price: 59,691 shares were sold in an exercise and sell transaction, covering the exercise price and taxes in accordance with the broker's procedures. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $66.865 to $67.09, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 59,691 | $48.49 | $2,894,416.59 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · nonDerivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,129 | $48.49 | $200,215.21 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · nonDerivative · entry 3 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired from options exercised in a net exercise and hold transaction with broker. F1 · price: Shares acquired from options exercised in a net exercise and hold transaction with broker. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,180 | $48.49 | $299,668.20 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired from options exercised in a net exercise and hold transaction with broker. F1 · price: Shares acquired from options exercised in a net exercise and hold transaction with broker. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 40,000 | $66.88 | $2,675,200.00 |
DisclosureSEC source: 0000014272-21-000202 · wf-form4_162915069428711.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,699 Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 20:55 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 46,403 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000195 · wf-form4_162802411019076.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 46,403 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock units vest in three equal installments beginning on August 1, 2019. F1 · derivative.expiration_date: The restricted stock units vest in three equal installments beginning on August 1, 2019. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 20:55 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 23,736 | $67.87 | $1,610,962.32 |
DisclosureSEC source: 0000014272-21-000195 · wf-form4_162802411019076.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,699 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 20:55 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 46,403 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000195 · wf-form4_162802411019076.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in three equal installments beginning on August 1, 2019. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 48,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000092 · wf-form4_161559343612853.xml · derivative · entry 7 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,257 Underlying: Common Stock, $0.10 par value · 48,257 shares Expires 2024-03-10 F6 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2024. F6 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2024. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 32,171 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000092 · wf-form4_161559343612853.xml · derivative · entry 6 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,171 Underlying: Common Stock, $0.10 par value · 32,171 shares Expires 2025-03-10 F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 8,025 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000092 · wf-form4_161559343612853.xml · derivative · entry 5 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,077 Underlying: Common Stock, $0.10 par value · 8,025 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,329 | $60.93 | $263,765.97 |
DisclosureSEC source: 0000014272-21-000092 · wf-form4_161559343612853.xml · nonDerivative · entry 3 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,032 F3 · shares: Shares withheld for payment of taxes upon vesting. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000092 · wf-form4_161559343612853.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,361 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 8,025 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000092 · wf-form4_161559343612853.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 24,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000070 · wf-form4_161481041413541.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,577 Underlying: Common Stock, $0.10 par value · 24,579 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: Each restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.exercise_date: Each restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.expiration_date: Each restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 8,573 | $61.63 | $528,353.99 |
DisclosureSEC source: 0000014272-21-000070 · wf-form4_161481041413541.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,186 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 24,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000070 · wf-form4_161481041413541.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 20,624 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000029 · wf-form4_160989562148858.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 20,624 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 11,931 | $62.03 | $740,079.93 |
DisclosureSEC source: 0000014272-21-000029 · wf-form4_160989562148858.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,180 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:13 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 20,624 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000029 · wf-form4_160989562148858.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 8,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000297 · wf-form4_160704502687137.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,376 Underlying: Common Stock, $0.10 par value · 8,792 shares Expires 2023-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 5,087 | $62.18 | $316,309.66 |
DisclosureSEC source: 0000014272-20-000297 · wf-form4_160704502687137.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,487 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 8,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000297 · wf-form4_160704502687137.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 46,402 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000225 · wf-form4_159657365724597.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,403 Underlying: Common Stock, $0.10 par value · 46,402 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019. F1 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 25,916 | $58.66 | $1,520,232.56 |
DisclosureSEC source: 0000014272-20-000225 · wf-form4_159657365724597.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,782 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 46,402 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000225 · wf-form4_159657365724597.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:14 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 48,152 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000120 · wf-form4_158405127070532.xml · derivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,152 Underlying: Common Stock, $0.10 par value · 48,152 shares Expires 2023-03-10 F3 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023. F3 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:14 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 32,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000120 · wf-form4_158405127070532.xml · derivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,102 Underlying: Common Stock, $0.10 par value · 32,102 shares Expires 2024-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 24,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000089 · wf-form4_158328387038941.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,156 Underlying: Common Stock, $0.10 par value · 24,579 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.exercise_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. F1 · derivative.expiration_date: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 10,470 | $59.06 | $618,358.20 |
DisclosureSEC source: 0000014272-20-000089 · wf-form4_158328387038941.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,296 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 24,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000089 · wf-form4_158328387038941.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in three equal installments beginning on March 1, 2020. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 12,373 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000028 · wf-form4_157809600587903.xml · derivative · entry 4 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 12,373 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. F2 · derivative.expiration_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 6,094 | $64.19 | $391,173.86 |
DisclosureSEC source: 0000014272-20-000028 · wf-form4_157809600587903.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,187 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 00:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 12,373 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-20-000028 · wf-form4_157809600587903.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · shares: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:59 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 35,168 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000240 · wf-form4_157549673340772.xml · derivative · entry 1 Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 Underlying: Common Stock, $0.10 par value · 35,168 shares Expires 2023-12-02 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on December 2, 2020. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 39,642 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · derivative · entry 8 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Commo Stock · 39,642 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 49,895 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · derivative · entry 7 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,895 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 103,913 | $0.00 Strike: $90.19 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · derivative · entry 6 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,913 shares Expires 2028-08-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 195 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · nonDerivative · entry 5 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 57,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · nonDerivative · entry 4 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 25,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · nonDerivative · entry 3 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,132 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 11,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · nonDerivative · entry 2 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,648 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001377 · form4-11222019_071113.xml · nonDerivative · entry 1 Elkins David V · CIK 0001451604 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,560 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.